P205 Impact of disease modifying treatment by three months of life on swallowing in spinal muscular atrophy type 1

Spinal Muscular Atrophy (SMA) Type I is a progressive neuromuscular disorder that causes rapid deterioration in an infant's ability to successfully orally feed with eventual death. Recent pharmaceutical advances have resulted in the development of disease modifying therapies (DMT) that are designed to halt neuromuscular deterioration upon administration and enable infant survival. Little is known, however, on the impacts of DMT on swallowing physiology and function. The aim of this investigation was to compare swallowing between infants who received DMT by 3 months of life and those who did not.

Source: Neuromuscular Disorders - October 1, 2023 Category: Neurology Authors: K. McGrattan, A. Spoden, H. McGhee, K. Nichols, K. Hernandez, J. Ochura, R. Graham, B. Darras, A. Brown, J. Brandsema, P. Karachunski, J. Allen, A. Miles Tags: SMA – CLINICAL Source Type: research